|
| 35932099 | Multiple primary melanoma in association with other personal and familial cancers. | Cancer Med | 2023 |
| 37857525 | Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma. | J Immunother Cancer | 2023 |
| 37662409 | Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma. | bioRxiv | 2023 |
| 37435077 | Expression of lymphoid structure-associated cytokine/chemokine gene transcripts in tumor and protein in serum are prognostic of melanoma patient outcomes. | Front Immunol | 2023 |
| 37397389 | Metformin is associated with improved clinical outcomes in patients with melanoma: a retrospective, multi-institutional study. | Front Oncol | 2023 |
| 36960318 | Development and Narrow Validation of Computer Vision Approach to Facilitate Assessment of Change in Pigmented Cutaneous Lesions. | JID Innov | 2023 |
| 35316223 | Tim-3 mediates T cell trogocytosis to limit antitumor immunity. | J Clin Invest | 2022 |
| 36356143 | TPP1 promoter mutations cooperate with TERT promoter mutations to lengthen telomeres in melanoma. | Science | 2022 |
| 36291758 | Sentinel Lymph Node Gene Expression Signature Predicts Recurrence-Free Survival in Cutaneous Melanoma. | Cancers (Basel) | 2022 |
| 35879777 | Co-expression of TNF receptors 1 and 2 on melanomas facilitates soluble TNF-induced resistance to MAPK pathway inhibitors. | J Transl Med | 2022 |
| 35319783 | Poorer survival outcomes in patients with multiple versus single primary melanoma. | Cancer | 2022 |
| 32557708 | Predicting Metastasis in Melanoma by Enumerating Circulating Tumor Cells Using Photoacoustic Flow Cytometry. | Lasers Surg Med | 2021 |
| 33753453 | Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma. | Clin Cancer Res | 2021 |
| 33170961 | Indoor tanning exposure in association with multiple primary melanoma. | Cancer | 2021 |
| 34124690 | Activation of p38α stress-activated protein kinase drives the formation of the pre-metastatic niche in the lungs. | Nat Cancer | 2020 |
| 30571927 | Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gα<sub>q</sub> and Gα<sub>11</sub> and kill uveal melanoma cells. | Cancer Biol Ther | 2019 |
| 30761123 | CD56<sup>dim</sup> CD16<sup>-</sup> Natural Killer Cell Profiling in Melanoma Patients Receiving a Cancer Vaccine and Interferon-α. | Front Immunol | 2019 |
| 30721155 | Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma. | JCI Insight | 2019 |
| 29219657 | The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib. | Cancer Biol Ther | 2018 |
| 30046006 | CD226 opposes TIGIT to disrupt Tregs in melanoma. | JCI Insight | 2018 |
| 30359157 | Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma. | J Clin Oncol | 2018 |
| 29691233 | Evaluation of Biodistribution of Sulforaphane after Administration of Oral Broccoli Sprout Extract in Melanoma Patients with Multiple Atypical Nevi. | Cancer Prev Res (Phila) | 2018 |
| 28923120 | High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute. | J Immunother Cancer | 2017 |
| 28489678 | Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-α2b in patients with metastatic melanoma. | Melanoma Res | 2017 |
| 28146421 | The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo. | Oncotarget | 2017 |
| 28825947 | A unique gene expression signature is significantly differentially expressed in tumor-positive or tumor-negative sentinel lymph nodes in patients with melanoma. | Melanoma Res | 2017 |
| 28552348 | Interferon-γ Drives T<sub>reg</sub> Fragility to Promote Anti-tumor Immunity. | Cell | 2017 |
| 28344862 | Expression profiles of immune-related genes are associated with neoadjuvant ipilimumab clinical benefit. | Oncoimmunology | 2016 |
| 25728676 | Transcriptional repression of IFNβ1 by ATF2 confers melanoma resistance to therapy. | Oncogene | 2015 |
| 26380086 | Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. | J Immunother Cancer | 2015 |
| 26419843 | Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma. | J Transl Med | 2015 |
| 26192408 | Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon-α but Not Observation in Intermediate Risk Melanoma Patients. | PLoS One | 2015 |
| 25866972 | TIGIT and PD-1 impair tumor antigen-specific CD8⺠T cells in melanoma patients. | J Clin Invest | 2015 |
| 25720800 | IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells. | Cancer Res | 2015 |
| 24498358 | Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. | PLoS One | 2014 |
| 24509407 | Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfa. | Melanoma Res | 2014 |
| 24343228 | PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⺠T cells induced by melanoma vaccines. | Cancer Res | 2014 |
| 24457057 | A four-marker signature of TNF-RII, TGF-α, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma. | J Transl Med | 2014 |
| 22184371 | Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. | J Clin Oncol | 2012 |
| 22912665 | Mitochondrial respiration--an important therapeutic target in melanoma. | PLoS One | 2012 |
| 22495394 | Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. | J Immunother | 2012 |
| 22210094 | Pitfalls in retrospective analyses of biomarkers: a case study with metastatic melanoma patients. | J Immunol Methods | 2012 |
| 22205715 | CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. | Cancer Res | 2012 |
| 20445352 | Pharmacodynamic (phase 0) study using etaracizumab in advanced melanoma. | J Immunother | 2010 |
| 20819923 | Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. | J Exp Med | 2010 |
| 19047287 | Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694. | J Clin Oncol | 2009 |
| 19380770 | PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. | J Immunol | 2009 |
| 19228745 | Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. | Clin Cancer Res | 2009 |
| 18779741 | Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients. | J Immunother | 2008 |
| 16908595 | Mitotic arrest, apoptosis, and sensitization to chemotherapy of melanomas by methionine deprivation stress. | Mol Cancer Res | 2006 |